Dalfampridine in the Treatment of primary fatigue in Patients with Multiple Sclerosis: A Randomized Clinical trial (PP-05)

Document Type : Poster Presentation

Authors
Shirin Mavandadi
Sepideh Paybast
Monirsadat Mirzadeh
Hossein Mozhdehipanah
.
Abstract
Introduction: Fatigue is a highly prevalent debilitating symptom among patients with multiple sclerosis (PwMS), which markedly affects the quality of life. The present study aimed to evaluate the effect of extended-release fampridine on fatigue in PwMS.
Methods: This was a randomized, double-blind clinical trial on 77 PwMS with a complaint of fatigue, aged over 18 years old, randomized to extended-release fampridine (n = 44) or placebo (n = 35) for 12 weeks. Fatigue and motor function were assessed at baseline and end point.
Results: A total of 88 patients were recruited, of whom 77 were analyzed. 80.5% were female, with a median age of 38. 87% were diagnosed with relapsing–remitting MS (RRMS) with a median disease duration of 96 months. Fingolimod (37.7%) was considered the most frequently used DMT, followed by ani-CD20s (32.5%). The total median MFIS score was 43.5 and 37 in the fampridine and placebo groups which were not significantly different (p > 0.05). After 12 weeks, the total MFIS improved in both groups compared to the baseline, which was significant in the active group (p = 0.04). However, the final endpoint total MFIS was still comparable between the two groups (p = 0.11). 
Conclusion: The present study revealed a positive short-term effect of extended-release fampridine on MFIS in PwMS. However, this effect was not significantly superior to the placebo.

Keywords

  • Receive Date 05 December 2024
  • Publish Date 01 October 2024